
---
title: '《狂犬病疫苗》 疫苗的不良反应和禁忌证'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=708852'
author: 科学网
comments: false
date: Mon, 19 Apr 2021 05:22:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=708852'
---

<div>   
<h2 style="margin-top: 15px;margin-right: 0;margin-bottom: 23px;text-indent: 24px;padding: 0;line-height: 200%;background: rgb(255, 255, 255)"><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 24px">大型学术专著《当代新疫苗》（第二版）于去年</span></strong><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 24px">3月正式出版。</span></strong></h2><h2 style="margin-top: 15px;margin-right: 0;margin-bottom: 23px;text-indent: 24px;padding: 0;line-height: 200%;background: rgb(255, 255, 255)"><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 24px"><span style="font-family:KaiTi">本人与中国食品药品检定研究院的李玉华研究员共同撰写了该书第</span><span style="font-family:KaiTi">40章《狂犬病疫苗》。</span></span></strong></h2><h2 style="margin-top: 15px;margin-right: 0;margin-bottom: 23px;text-indent: 31px;padding: 0;line-height: 200%;background: rgb(255, 255, 255)"><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px">本博客将分若干次全文转载这一章的内容。今天转载的是本章的第</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px">１</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px">节</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px">:</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px"> <span style="font-family:KaiTi">疫苗的不良反应和禁忌证</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px">。</span></strong></h2><p style="margin-top: 15px;margin-right: 0;margin-bottom: 15px;padding: 0;line-height: 200%;background: rgb(255, 255, 255)"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 29px">11.　</span><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 29px">疫苗的不良反应和禁忌证</span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">早先使用的神经组织疫苗（</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">NTV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">经常引起较严重的不良反应</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(adverse reaction)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">，而且免疫原性弱于细胞培养狂犬病疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(CCRV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。因此，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">WHO</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">不推荐生产和使用神经组织疫苗。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">  </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">国内自</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1980</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年以后已全面推广了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">一般而言，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">是安全的疫苗，严重的不良事件主要是过敏或神经症状，实际上较为罕见</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Rupprecht & Plotkin,2018)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。对于暴露前预防，对疫苗中任何成分有严重反应史应视为接种同种疫苗的禁忌证。</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">因为狂犬病是一种致命性疾病，所以对高危暴露者进行</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">没有禁忌证。对各种可能的严重过敏反应，要进行主动的预防并做好各种应急准备。</span></span></strong></p><p><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">11.1　普通群体的不良反应</span></span></strong></p><p><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">11.1.1　</span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">一般性不良反应</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">相关研究通常报告</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">35</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">45</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％的受试者在注射部位发生局部反应，可出现一过性的红斑、疼痛、肿胀（采用皮内接种通常较采用肌内接种更严重）。常见的轻微的全身反应通常发生在</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">10</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">15</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％的受试者中，包括一过性发热、头痛、头晕、肌痛、全身乏力、荨麻疹、皮疹和胃肠道症状。</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">曾大规模测试人二倍体细胞疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(HDCV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">对美国兽医学生接种后的安全性和免疫原性，在超过</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1770</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">名志愿者中观察到的不良反应及发生率如下：</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">明显的手臂酸痛</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(15</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">25</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">；头痛</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">8</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％）；抑郁、恶心，或两者兼而有之</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(2</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">；过敏性水肿</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(0.1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％）。</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">在另一项对暴露后接种者的研究中，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">21</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％有局部反应，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">36</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％有发热，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">7</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％有头痛，</span> </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％有恶心。最常见的局部反应是红斑、疼痛和硬结。这些结果已被近期的研究证实。</span> <span style="font-family:KaiTi">当</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HDCV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">接种给儿童时，他们的心理问题可能比成人少，所以对副反应的主诉较少。</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">美国疫苗不良事件报告系统</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(VAERS)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">被动收集同一疫苗的数据。头痛是报告的最突出的症状。神经性反应似乎与疫苗无关，报告的其他反应通常是不严重的。</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">一项研究将鸭胚疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(PDEV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">与</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">Vero</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">细胞疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(PVRV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">及</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">纯化鸡胚细胞疫苗</span>(PCECV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">进行了比较，副反应无明显差异。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PCECV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">在泰国儿童中与日本脑炎疫苗同时接种也显示是安全的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Rupprecht & Plotkin,2018)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">11.1.2　过敏反应 </span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HDCV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">在美国获得批准并广泛使用后，开始出现过敏反应的报告，主要出现在进行加强免疫之后</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Fishbein et al.,1993)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。接种者副反应的总发生率是</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">0.11</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％</span> <span style="font-family:KaiTi">，但在加强接种后，发生率上升到</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">6</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％</span> <span style="font-family:KaiTi">。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">10</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％的报告病例发生Ｉ型（</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">IgE</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">）过敏性反应，全部发生在初次系列接种的过程中（</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">万次接种中发生</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">例），但在加强接种后</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">21</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> <span style="font-family:KaiTi">天发生的大多数是</span><span style="font-family:KaiTi">Ⅲ型超敏反应（</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">Ig</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">Ｇ、</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">Ig</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">Ｍ）。这些反应被归因于人血白蛋白的抗原性，因为在疫苗生产过程中，在使用</span><span style="font-family:KaiTi">β丙内酯灭活病毒时，添加了人血白蛋白作为稳定剂，这增加了白蛋白形成免疫复合物的能力。幸运的是，呼吸道症状通常很轻微，从未发生死亡病例。抗组胺剂、肾上腺素以及偶尔应用的类固醇药物都可成功地处置这些反应，症状通常都在</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">天缓解。</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">较新的疫苗在生产过程中使用了额外的纯化步骤以去除人血白蛋白。</span> <span style="font-family:KaiTi">用这些疫苗进行加强接种后极少发生全身反应。据报道，美国疫苗不良事件报告系统</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(VAERS)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">收集到</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">20</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">例接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PCECV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">后可能与疫苗相关的过敏反应报告。有严重过敏史的个体更容易对狂犬病疫苗产生过敏反应。这些个体进行免疫接种时，应预防性使用抗组胺药物，并准备肾上腺素。如果在按程序接种多剂疫苗的中途发生过敏反应，则在后续接种时应向患者提供不同组织来源的替代疫苗，例如，如果对</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HDCV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">有过敏反应，则提供</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PVRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> <span style="font-family:KaiTi">或</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PCECV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">然而，只有发生预先用药不能控制的非常严重的反应时，才需要考虑中断狂犬病疫苗的免疫接种。使用类固醇治疗可能控制过敏，但也可能抑制</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">应答。相应地，如果使用了类固醇，则应在最后</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">剂疫苗注射后测定</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">滴度。</span> <span style="font-family:KaiTi">因其他疾病而接受免疫抑制治疗的患者也应在免疫后检测</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">水平，以证实对疫苗产生了充分的抗体应答。如果滴度不足，则应注射加强疫苗。</span></span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">11.1.3　神经系统反应</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">在数以百万计的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HDCV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">接种者中，共报告了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">例发生</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CNS</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">疾病，包括短暂性神经麻痹性疾病吉兰－巴雷综合征。这些疾病的基础发生率就是每年每</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">10</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">万人</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">例，这个发生率太低，可能与接种疫苗无因果关系。在泰国，从原来使用</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">NTV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">改为使用</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">后，导致神经系统并发症的发病率从</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">155</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">人中</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">例下降到</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">万人中少于</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">例</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Rupprecht & Plotkin,2018)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi"><br></span></span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">11.2　狂犬病疫苗无禁忌证</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">狂犬病是病死率最高的传染病，但感染狂犬病病毒后迅速接受</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">WHO</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">推荐的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">方案后极少发生死亡，这证明</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">是世界上免疫保护效果最好的疫苗之一。现代人用狂犬病疫苗是灭活疫苗，不良反应轻微，从该病可导致</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">100</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％死亡率的概念出发，暴露后疫苗免疫应无禁忌证。</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">下面举例分析几种特殊群体对该疫苗的免疫反应和注意事项。</span></span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">11.2.1　免疫功能低下者</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">狂犬病疫苗几乎在所有人群中均具有很高的免疫原性，但</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CD4</span></strong><span style="font-size: 16px;"><strong><sup><span style="line-height: 200%; letter-spacing: 0px; vertical-align: super; background: #FFFFFF; font-family: KaiTi;">＋</span></sup></strong></span><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> <span style="font-family:KaiTi">细胞计数极低的人群可能例外</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Deshpande et al.,2001)</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">。在一项研究中，研究者选择了人类免疫缺陷病毒（</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HIV</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">）感染的成年人群进行</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">的免疫反应调查，在</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CD4</span></strong><span style="font-size: 16px;"><strong><sup><span style="line-height: 200%; letter-spacing: 0px; vertical-align: super; background: #FFFFFF; font-family: KaiTi;">＋</span></sup></strong></span><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">细胞计数低于</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">400</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">的有症状的</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HIV</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">感染病人中，在接受了</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">方案，即分别于第</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">0</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">、</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">、</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">7</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">、</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">14</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">和</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">30</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">天肌内注射</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">5</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">剂疫苗后，只有</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">57</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">％的病人产生了高于</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">0.5 IU/mL</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">的</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。另一项研究中，</span> </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">10</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">名</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CD4</span></strong><span style="font-size: 16px;"><strong><sup><span style="line-height: 200%; letter-spacing: 0px; vertical-align: super; background: #FFFFFF; font-family: KaiTi;">＋</span></sup></strong></span><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">细胞计数在</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">25</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">～</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">472</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">的</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HIV</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">感染成年病人接受了一项多点皮内接种</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">方案，他们分别于</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">0</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">、</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">和</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">7</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">天皮内接种了</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">4</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">剂</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> <span style="font-family:KaiTi">，第</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">28</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">和</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">90</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">天分别皮内接种</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">剂</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">（“</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">4-4-4-0-2-2</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">”）。该项研究报告指出，</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">10</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">名受试者的免疫反应均低于预期；其中，</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">名病人的</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> <span style="font-family:KaiTi">滴度在第</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">14</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">天还没有超过</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">0.5 IU/mL</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">；</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">名病人在第</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">30</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">天还没有超过</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">0.5 IU/mL</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">。在另一项研究中，研究者对</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">13</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">名</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HIV</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">感染、</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CD4</span></strong><span style="font-size: 16px;"><strong><sup><span style="line-height: 200%; letter-spacing: 0px; vertical-align: super; background: #FFFFFF; font-family: KaiTi;">＋</span></sup></strong></span><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">细胞计数低于正常值的儿童采用</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">剂肌内注射</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">的</span> </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PrEP</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">方案，然后检测其免疫反应，并与</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">9</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">名未感染儿童的免疫反应进行对比。在该项研究中，与对照组相比，</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CD4</span></strong><span style="font-size: 16px;"><strong><sup><span style="line-height: 200%; letter-spacing: 0px; vertical-align: super; background: #FFFFFF; font-family: KaiTi;">＋</span></sup></strong></span><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">细胞计数低于正常值１５％的儿童的</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> <span style="font-family:KaiTi">滴度明显偏低，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">13</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">名</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HIV</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">感染儿童中的</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">4</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">名未产生可以检测到的</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">。</span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">在近期的一项研究中，研究者对进行过高活性抗反转录病毒治疗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(HAART)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HIV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">感染受试者进行</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">接种，并检测免疫反应，结果显示，在这些</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HIV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">感染时间较长的病人血清中的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">Ig</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">Ｇ和</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">Ig</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">Ｍ</span> <span style="font-family:KaiTi">滴度比正常值偏低。然而，该项研究也显示，这些接受过</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HAART</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">的病人中的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">63</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％在疫苗初次接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年后仍有可检测到的抗体滴度。</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">另一项研究评估了免疫抑制病人中一种更加有效的接种程序。受试者包括两组</span> </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HIV</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">阳性病人，一组的</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CD4</span></strong><span style="font-size: 16px;"><strong><sup><span style="line-height: 200%; letter-spacing: 0px; vertical-align: super; background: #FFFFFF; font-family: KaiTi;">＋</span></sup></strong></span><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">细胞计数低于</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">200</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">，另一组高于</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">200</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">。每名受试者接受一种改良的</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">8</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">位点复合皮内接种</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">方案，该方案包括分别于第</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">0</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">、</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">、</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">7</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">、</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">14</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">和</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">30</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">天时</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">8</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">点皮内注射</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">。所有受试者均有抗体滴度高于</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">0.5 IU/mL</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">的反应。也有报道显示，所有接受实体器官移植后进行免疫抑制治疗的儿童，在暴露于狂犬病病毒后接受</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: KaiTi;">方案，均有成功的免疫反应。</span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">免疫功能低下者（包括</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">AIDS</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">患者）如发生</span><span style="font-family:KaiTi">Ⅱ级和Ⅲ级暴露，应全程肌内接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">剂次</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> <span style="font-family:KaiTi">，同时进行综合性伤口处理和局部浸润注射人狂犬病免疫球蛋白。如条件允许，在接种后</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">4</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">周时应检测</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">反应，以评估是否需要进行额外的疫苗接种。</span></span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">11.2.2　服用疟疾治疗药物氯喹的病人</span></span></strong></p><p style="text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">此类病人经皮内途径接种狂犬病疫苗时，产生的抗体滴度较低。</span><span style="font-family:KaiTi">因此，此类病人应采用肌内内途径接种疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Rupprecht & Plotkin,2018)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">11.2.3　婴幼儿和老年人</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">据研究报告，在无特别的免疫抑制的状况下，婴幼儿和老年人对狂犬病疫苗的免疫反应是足够的。已发表的一份报告综合了对不同年龄受试者的免疫反应进行检测的两项研究，结果都表明，老年个体在接种疫苗后</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">水平偏低。在该报告述及的一项研究中，年龄为</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">11</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">25</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">岁的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">260</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">名受试者的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">处置包括接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">6</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">针疫苗，并将他们与接受同样处置的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">50</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">岁以上的人进行比较。在这项研究中，有</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">52</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％以上的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">50</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">岁以上成年人与年轻人相比，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">滴度显著降低。</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">另一项研究涉及</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">875</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">名病人，年龄为</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">74</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">岁，分别接受</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">或</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PrEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">，分别按年龄和性别进行分组比较，结果所产生的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">没有显著差异。</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">在确认为营养不良</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">4</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">级的儿童中，针对狂犬病</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">产生的免疫反应也是足够的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Rupprecht & Plotkin,2018)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">11.2.4　孕妇</span></span></strong></p><p style="margin-left:0;text-indent:57px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">狂犬病</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">对孕妇不是禁忌，在该群体中具有免疫原性、高度有效而且安全。</span> <span style="font-family:KaiTi">狂犬病</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">在应用于孕妇时不应有顾忌，因为它是一种拯救生命的疫苗。对</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">202</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">例泰国妊娠妇女进行的随访表明，接种狂犬病疫苗并没有增加并发症和畸形胎儿的发生率。</span> <span style="font-family:KaiTi">对新生儿进行免疫接种似乎没有必要，但凡进行了免疫接种的都获得成功</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Abazeed et al.,2007)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。尚无报告表明孕妇由于采用包括</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">接种在内的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">而引起流产或对胎儿产生其他伤害。</span></span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">相关博文：</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:20px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1277395" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》专著共享</span></span></a><span style="font-family: SimSun;color: #6666CC;letter-spacing: 0;font-size: 19px"> </span><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2021-03-18</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:20px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1277585" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著共享) 1. 概述</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> </span><span style="font-family: SimSun;color: #666666;letter-spacing: 0;font-size: 19px"> </span><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px">2021-03-19</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:20px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1277814" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著共享) 2.病原学</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> </span><span style="font-family: SimSun;color: #666666;letter-spacing: 0;font-size: 19px"> </span><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px">2021-03-21</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:20px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1277951" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著共享) 3.流行病学</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2021-03-22</span><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1278323" target="_blank"></a></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:29px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 4. 发病机理与疫苗免疫应答</span></strong><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2021-03-24</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:29px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1278633" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 5. 狂犬病的症状和临床诊断</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2021-03-26</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:29px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1279308" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=708852" title alt="image.png" referrerpolicy="no-referrer"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 6. 狂犬病疫苗制造(A)</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2021-03-30</span></p><p style="margin-left:0;text-indent:35px;text-autospace:ideograph-numeric;line-height:200%"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1279597" target="_blank"><strong><span style="text-decoration:underline;"><span style="font-family: Tahoma;line-height: 200%;color: #6666CC;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 6. 狂犬病疫苗制造(B)</span></span></strong></a><span style="font-family: Tahoma;line-height: 200%;color: #666666;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> 2021-04-01</span></p><p style="margin-left:0;text-indent:35px;text-autospace:ideograph-numeric;line-height:200%"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=708853" title alt="image.png" referrerpolicy="no-referrer"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1281048" target="_blank"><strong><span style="text-decoration:underline;"><span style="font-family: Tahoma;line-height: 200%;color: #6666CC;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 7-8. 狂犬病暴露后和暴露前的预防</span></span></strong></a><span style="font-family: Tahoma;line-height: 200%;color: #666666;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> 2021-04-09</span></p><p style="margin-left:0;text-indent:35px;text-autospace:ideograph-numeric;line-height:200%"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1281683" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=708854" title alt="image.png" referrerpolicy="no-referrer"><strong><span style="text-decoration:underline;"><span style="font-family: Tahoma;line-height: 200%;color: #6666CC;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 9. 狂犬病免疫球蛋白的应用</span></span></strong></a><span style="font-family: Tahoma;line-height: 200%;color: #666666;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> 2021-04-13</span></p><p style="line-height: 200%;"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">   </span></strong><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=708855" title alt="image.png" referrerpolicy="no-referrer"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1282035" target="_blank"><strong><span style="text-decoration:underline;"><span style="font-family: Tahoma;line-height: 200%;color: #6666CC;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著)10. 狂犬病疫苗的有效性和持久性</span></span></strong></a><span style="font-family: Tahoma;line-height: 200%;color: #666666;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> 2021-04-15</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-347754-1282663.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-347754-1282663.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1282420.html" target="_black">新冠病毒变异株B.1.1.7的毒力并未增强(Lancet新证据)</a><br>                    <!--大赛结束-->
                                        
  
</div>
            